ASX RELEASE

Volpara joins Epic App Market

Wellington, NZ, 31 October 2022: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global health technology software leader providing an integrated platform for personalised breast care, today announced that Volpara has signed an agreement with Epic to participate in the Epic App Market Program. This provides Volpara access to technologies, testing tools, and technical support to help enable its apps to interoperate effectively with Epic software and users' Epic workflows.

Epic and Volpara have over 100 shared customers, and this step enables Volpara to bring its products to the Epic App Market with stronger integration with Epic, as well as providing a platform to provide information about Volpara products directly to the Epic customer base.

Authorisation & Additional Information

This announcement was authorised by the CEO of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas	Hannah Howlett
Chief Executive Officer	Director, Investor Relations
Volpara Health Technologies	WE Communications
teri.thomas@volparahealth.com	WE-AUVolpara@we-worldwide.com
t: +64 4 499 6029	t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.

Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 16 million patients globally. It helps providers conduct more than three million cancer risk assessments

each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A$132 million. With offices in Seattle and Boston, Volpara is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.

Epic is a registered trademark of Epic Systems Corporation.